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Themonokine known astumornecrosis factor or cachectin (TNF) is apro-inflam-
matory immunological mediator, with the ability to stimulate in vitro functions of
human eosinophils (1, 2), neutrophils (3-7), monocytes (8), endothelial cells (4, 9,
10), and fibroblasts (11, 12) .
In an earlier study (1) we found that TNF increased the aggregation and adher-
ence to schistosomula (Schistosoma mansoni) of neutrophils obtained from all but 1
of 12 blood donors . Subsequent experiments with both eosinophils and neutrophils
from that single human subject (NR, for nonresponder) are described here . These
cells were usually unresponsive to TNF in assays of antibody-dependent toxicity to
schistosomula, aggregation, and adherence to plastic, or generation of hydrogen
peroxide in response to stimulus with aggregated IgG .
During studies of the mechanism underlying the apparent unresponsiveness to
TNF, we detected a factor inNR serum that inhibits the cytotoxic function ofTNF
stimulated eosinophils . This substance has been designated ECI (for eosinophil cy-
totoxicity inhibitor) .1 This article describes physical and functional characteristics
ofECI as well as evidence that ECI can be derived from an inactive precursor in
normal human serum .
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Materials and Methods
Cytokines.
￿
Recombinant human TNF, produced by Escherichia coli and purified to near
homogeneity (>90%, judged by SDS-PAGE), containing 42 ng/mg endotoxin (assayed by
LAL Assay Associates ofCape Cod, Inc ., Woods Hole, MA) (13), was provided by the pro-
cess development group at Cetus Corporation.
Unless otherwise specified, TNF was used at a concentration of 100 U/ml, the optimal
dose for the eosinophil cytotoxicity assay (1) . For some experiments, purified mAb 245-10EIl
(14) was used to neutralize the activity of TNF. The neutralizing titer of the antibody was
determined by the L929 cell cytotoxicity assay (see below) .
Address correspondence to David S . Silberstein, Seeley G. Mudd Bldg., Room 507, 250 Longwood
Avenue, Boston, MA 02115 .
1 Abbreviations used in this paper: ECI, eosinophil cytotoxicity inhibitor ; GM-CSF, granulocyte/mac-
rophage colony-stimulating factor.
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Recombinant human granulocyte/macrophage colony-stimulating factor (GM-CSF), pro-
duced by COS cells and purified, was provided by Dr. Judith C. Gasson (Division of Hema-
tology and Oncology, Department of Medicine, UCLA School of Medicine, Los Angeles,
CA). GM-CSF was used at a final concentration of20 pM, the optimal dose in the eosinophil
cytotoxicity assay (15).
Preparation ofHuman Serum, Eosinophils, and Neutrophils.
￿
Venous blood was obtained from
laboratory personnel for the preparation ofserum, eosinophils and neutrophils. Some ofthe
donors for eosinophil studies had moderately elevated eosinophil counts in association with
allergies and/or asthma (total eosinophil counts ranged from 1 to 18% of total leukocytes
for these studies). The subject whose cells failed to respond to TNF (NR) was also a labora-
tory staffmember with ahistory of severe delayed-type hypersensitivity dermatitis reactions.
Blood for the preparation of serum was collected in glass tubes, incubated at 37' for 1 h,
and then overnight at 40. The serum was clarified by centrifugation and stored frozen at -20°.
Eosinophils were isolated by a sequence ofdextran sedimentation and discontinuous metriza-
mide density gradient centrifugation (16). Erythrocytes were removed by hypotonic lysis. The
purity of eosinophil preparations, as evaluated by examination of Wright's-Giemsa stained
slides, ranged from 80 to 99%, with neutrophils as the contaminating cells.
Neutrophils were prepared by a sequence of dextran sedimentation and Ficoll-Hypaque
centrifugation (17). Erythrocytes were removed by hypotonic lysis. The neutrophil prepara-
tion were essentially free of mononuclear cells and contained <10% eosinophils.
Two serum samples from patients with hypereosinophilia (one with idiopathic hyper-
eosinophilic syndrome and one with eosinophil infiltration ofthe lingual/buccal tissues) were
provided by Dr. William F Owen (Department of Rheumatology and Immunology, Brigham
and Women's Hospital, Boston, MA).
100 anonymous serum samples were supplied by the American Red Cross Blood Services,
Northeast Region (Dedham, MA; special thanks to Dr. Mark A. Popovsky and to Celeste
LeFort), for use in studies related to Fig. 2 and Table I. Pooled human type AB serum (lot
no. 29309039) was obtained from Flow Laboratories (McLean, VA).
Human plasmas deficient in coagulation factors XI, XII, prekallikrein, or high molecular
weight kininogen were obtained from George King Biomedical, Inc. (Overland Park, KS).
The plasmas were recalcified to a final concentration of 0.4 M CaC12, and the clots that
formed were removed by centrifugation. Control experiments with normal sera and recalcified
plasmas showed that this procedure did not affect the functional properties of the serum in-
hibitor (ECI).
Lipoprotein-free human serum and purified high density, low density, and very low den-
sity lipoproteins were obtained from Sigma Chemical Co. (St. Louis, MO). Antibody to schis-
tosomula ofS. mansoniwas obtained from Brazilian schistosomiasis patients, as described pre-
viously (1).
Assay ofEosinophil or Neutrophil Cytotoxic Function.
￿
Antibody-dependent killing ofS. mansoni
larvae was measured as described previously (1), usingheat-inactivated serum from Brazilian
schistosomiasis patients as a source of antibody. Effector cells (E/T ratio of 1,000:1 for eo-
sinophils and 5,000:1 for neutrophils), antibody (diluted 1/100), schistosomula targets (100/well),
and cytokine were cultured (medium: MEM with Earle's salts, supplemented with 25 mM
Hepes, 2 mM glutamine, 100 U/ml penicillin, 100 Fig/ml streptomycin, and 10% FCS serum
fall from Gibco Laboratories, Grand Island, NY]) for 36-40 h. After this period, killing was
scored by microscopy. Control or test samples ofinhibitors were added to the cultures at var-
ious times in an additional volume of 50 Al, usually dissolved or dialyzed in medium. For
experiments in which the inhibitor was removed, the contents of microwells were transferred
to 12 x 75 mm polypropylene tubes at various times, diluted with 5 ml ofmedium, and cen-
trifuged at 500 g for 5 min. The supernatant was aspirated, and the eosinophils and schistoso-
mula in the pellet were recultured in 250,ul ofassay medium with fresh antibody and cytokine.
Assay ofEosinophil and Neutrophil Adherence to Plastic.
￿
Eosinophils or neutrophils were sus-
pended at a concentration of 105 cells/200 pl of assay medium in the presence or absence
of 100 U/ml TNF and allowed to settle in round-bottomed microtiter wells at 37°C for 2 h.
After this period, the adherence of eosinophils to the plastic surface was assayed by one of
two methods. As described previously (1), using an inverted microscopethe wells were exam-SILBERSTEIN ET AL.
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ined for the presence of adherent cells covering the sides ofthe wells. In the absence of TNF,
there was very little adherence of eosinophils or neutrophils to the plastic, and most of the
cells were in a pellet at the bottom of the wells. As an alternative method of measuring the
adherence to plastic, nonadherent cells were washed away with warm saline, and a solution
containing 0.1% Triton X-100, 0.4 mM 2-2' azino-di-3-ethyl-benzthiazoline-6-sulfonate plus
0.003% hydrogen peroxide in pH 4.0, 0.05 M sodium citrate was added to the wells. The
generation of colored product (absorbance monitored at 405 nm) reflected the quantity of
cell-derived peroxidase in the wells.
Measurement ofEosinophil andNeutrophil Production ofH202.
￿
Production of H202 was mea-
sured by quenching of scopoletin fluorescence (18), with purified cells washed and resuspended
in buffer (4 mM sodium phosphate, pH 7.4, 128 mM sodium chloride, 12 mM potassium
chloride, 1 mM calcium chloride, 2 mM magnesium chloride, and 2 mM glucose) at a con-
centration of 106/ml. The cells (2 ml) were then placed in a cuvette (10 x 10 x 48 mm acrylic;
Sarstedt, Princeton, NJ) with 5 pl of horseradish peroxidase stock (6.25 mg/ml buffer, Sigma
Chemical Co.), 10 pl of scopoletin stock (1 mM in buffer, Sigma) and 10 Al of control buffer
or TNF (for some experiments); they were maintained at 37°C. Fluorescence was monitored
at 460 nm (with excitation at 350 nm) by a fluorescent spectrophotometer (No. MPF4413;
Perkin-Elmer, Norwalk, CT). When baseline fluorescence had been established for 5 min,
the cells were stimulated either with 10 id of phorbol myristate acetate (1 mg/ml in ethanol)
or 10 141 of IgG aggregates (10 mg/ml). The decrease in fluorescence, which is proportional
to the production of H202, was recorded by a Perkin-Elmer model 056-1001 recorder.
To prepare IgG aggregates, chromatographically purified human IgG (Organon Teknika-
Cappel, Malvern, PA) was dissolved in H202 assay buffer at a concentration of 10 mg/ml.
This solution was heated in a water bath at 62°C for 25 min. Control preparations of IgG
that were not heat-aggregated did not stimulate detectable production of H202 by eosinophils
or neutrophils.
Assay of TNF Toxicity to L929 Cells.
￿
The toxicity of TNF to L929 cells was assayed as de-
scribed (13). The cells were cultured either with 1 ug/ml actinomycin D for 16 h (seeded ini-
tially at 105 cells/microwell) or without actinomycin D for 48 h (seeded originally at 2 x 104
cells/microwell). The viability of L929 cellswas determined by the spectrophotometric mea-
surement of the reduction of the tetrazolium salt MTT (3-4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide) to formazan by the mitochondrial enzyme succinate de-
hydrogenase, a reaction that occurs only in living cells (19).
HPLC .
￿
For molecular size analysis and partial purification of ECI, 100-11 samples of
serum were chromatographed on a TSK-400 BicSi17 x 600 mm column (Bio-Rad Laborato-
ries) with a solvent consisting of 0.9% sodium chloride, 25 mM Hepes at pH 7.2, 100 U/ml
penicillinG, and 100,ug/ml of streptomycin. The column was calibrated using purified human
serum albumin, IgG, and IgM, as well as the identifiable peaks of these substances resolved
from human serum.
For anion-exchange separations, the sample was injected on a DEAE-5PW 7.5 x 75 mm
column (Bio-Rad Laboratories). The column was washed for 15 minutes with 0.02M Tris,
pH 8.0, eluted with a 45-min gradient to Tris buffer plus 0.5 M ammonium sulfate, and
washed for an additional 15 min with Tris/ammonium sulfate, all at a flow rate of 1 ml/min.
Eluted fractions to be assayed for ECI activity were dialyzed in assay medium.
Heat or Trypsin Treatment ofECI.
￿
Active fractions from the HPLC sizing analysis (see Fig.
3) were pooled, and aliquots were treated with heat (80°C water bath for 1 h) or treated with
trypsin (TPCK-treated trypsin, type XIII, Sigma Chemical Co. ; trypsin treatment consisted
oftwo 30-min incubations with 0.5% trypsin at 37°C). Soybean trypsin inhibitor (type I-S,
Sigma) was added at fourfold excess neutralizingunits either before or aftertrypsin treatment.
Results and Discussion
Apparent Unresponsiveness ofNR Eosinophils andNeutrophils to TNF.
￿
Stimulation of
normal eosinophils with 100 U/ml ofTNF enhanced their antibody-dependent killing
of schistosomula from 14.3 t 8.4% to 45.5 t 16.8% of targets killed (40 experi-684
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ments with eosinophils purified from 21 different donors, p < 0.001 by thetwo-tailed
t-test, factor ofincrease ranged from 64to 1,150%). By comparison, NR eosinophils
failed to respond to TNF at doses up to 10,000 U/ml in 9 of 12 parallel experiments
(19.3 t 9.1% killed without TNF; 19.0 t 7.7% killed with 100 U/ml TNF, for ex-
ample). In the other three experiments, which were conducted when NR was ex-
periencing different episodes ofsevere inflammation due tobruising or allergic der-
matitis, the cytotoxic function of unstimulated NR eosinophils was elevated (42.7
t 12.1% killed), and there was also a detectable response to TNF (increase to 63
t 20.3% killed).
Neutrophils from NR were similarly unresponsive to TNF, asjudged by the failure
to aggregate and adhere to plastic (12 of 13 experiments), the failure to increase the
killingofschistosomula(3 experiments), and the failure to release increased quanti-
ties of H202 following stimulus with aggregated IgG (5 experiments).
The unresponsiveness to TNF was not associated with use ofdrugs or medica-
tions, unusual habits of diet, exercise, or sleep, or any known infections. In view
oftheoccasional responsiveness toTNF inassociation withinflammation, TNF un-
responsiveness by NR eosinophils appeared toresult from a regulatory mechanism,
rather than a constitutive defect (such as a genetically defective TNF receptor).
Presence ofa Factor (ECI) in NR Serum that Reduced the Cytotoxic Function ofNormal
TNF-stimulatedEosinophils. Inthe eosinophil cytotoxicity assay, theaddition ofNR
serum (at the time that eosinophils and schistosomula were mixed) suppressed the
killing of schistosomula targets by normal TNFstimulated eosinophils. This effect
was half-maximal at a serum concentrationof2-5% and maximal at >10%. Gener-
ally, other human seradid not have this effect (Fig. 1). However, inhibitory activity
(ECI) was also detectable in a sample of pooled human (type AB) serum (a tissue
culture reagent purchased from Flow Laboratories) and in samples from two pa-
tients with extremehypereosinophilia (one with theidiopathic hypereosinophilic syn-
drome and one with eosinophil infiltration of the lingual/buccal tissues).
To gain further information about the population distribution ofthe inhibitory
activity identified in NR serum, 22 sera from lab personnel and 100 anonymous
sera from the Red Cross were tested in the eosinophil cytotoxicity assay. 11 ofthese
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The ability ofheat-
inactivated NR serum to cross-
inhibit the response of normal
eosinophils to TNF. The cyto-
toxic function ofeosinophils was
assayed in the presence or ab-
sence of 100 U/ml of TNF.
Normal serum or NR serum
was added to the cultures at the
indicated concentrations. The
horizontal lines indicate the
level of killing with no serum
added in the presence (---) or
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sera reduced TNFenhanced killing of targets by >50%, and 4 sera reduced TNF
enhanced killing by >90% (Fig . 2) .
Physical Characteristics of the Inhibitory Component (ECI) in NR Serum.
￿
The molec-
ular weight oftheinhibitory componentwas investigated bychromatography ofNR
serum on HPLC sizing columns . When the serum was heat-inactivated (56°C for
30 min, necessary for subsequent bioassay) before sizing, the molecular weight ap-
peared to range from 80,000 up to the void volume of the column (>900,000) (not
shown) . When fractions were heat-inactivated after sizing, the molecular weight ap-
peared to be "80,000 to 100,000 (Fig . 3) . Samples of seven different control sera,
with no detectable titers of inhibitor, were chromatographed in a similar manner.
Surprisingly, inhibitor of approximately the same molecular weight was detected
(example in Fig . 3) .
Titration experiments showed that the activity of the inhibitor was increased by
the molecular sizing procedure . In the case of whole sera with detectable ECI, the
activity increased by a factor of 50 to 2,000 . In thecase of whole sera with no detect-
able ECI, the inhibitory activity emerged followingtheHPLC sizing procedure (Fig .
4) . This apparent activation or unmasking of ECI also occurred when serum was
fractionated by anion exchange HPLC (Fig. 5A and B) . The activation ofECI by
sizing or anion-exchange HPLC suggests that these separatory methods removed
a component that stabilizes inactive ECI or suppresses the activity of ECI.
Alternatively, the conditions of sample handlingand chromatography might have
artifactually generated a substancewith inhibitory functionsin ourbiological assays .
This possibility was tested in several different ways, and the following procedures
all failed to activate ECI in normal sera : (a) dialysis or dilution ofserum with medium
or chromatography buffer, (b) exposure of serum to steel or silica components of
HPLC columns without chromatographic separation, or (c) salting out of serum
with ammonium sulfate (thoughthe 50-70% saturated ammonium sulfate fraction
contained material that could be activated by subsequent HPLC). It has also found
that HPLC size fractionation of chromatography buffer, and of rabbit, mouse, or
fetal calf sera did not generate ECI. Thus, ECI was not generated or activated by
removal of electrolytes or other low molecular weight substances, by dilution, by
FIGURE 2 . Population distri-
bution of the eosinophil cyto-
toxic inhibitory activity in
human sera . 100 anonymous
serum samples (HIV and hep-
atitis B negative) were obtained
from the Red Cross and tested
at a concentration of 10% for
the ability to inhibit the cyto-
toxic function ofTNFactivated
eosinophils .686
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exposure to dialysis membrane, steel, or silica, by some otherproperty ofthe HPLC
columns, or by nonspecific reactionsinvolvingmolecules foundin serum from other
mammalian species.
We also considered an example of a nonspecific reaction that was described in
another in vitro system (20, 21). It was demonstrated that low densitylipoproteins,
whichmay become oxidized during chromatography in aeratedbuffers(21), can sup-
press cytotoxic functions of human monocytes with respect to tumor cell targets.
However, we foundthat high density, low density, and very low densitylipoproteins
did notsuppress thecytotoxic function ofTNRstimulated eosinophils, either directly
or after size exclusion HPLC (using de-gassed buffers according to our standard
practice). The lipoprotein elution times did not overlap the elution time of ECI.
However, size exclusion HPLC of lipoprotein-free serum generated ECI of 80,000-
100,000 daltons. Therefore, the phenomenon oflipoprotein oxidation is not related
to ECI.
We investigated the reversibility of the activation of ECI. When NR serum was
mixed with normal sera in various proportions, the ECI titer was not diminished.
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%serum (or equivalents ) in culture
Similarly, whenECI prepared from NR ornormal serumwasmixedwith theserum
from which it was derived or with other HPLC fractions, the major part of ECI
activity remained. Thus, the conversion to active ECI appeared to be irreversible.
ECIactivitywas reduced byheatingat 80'C for 1 hor by treatmentwith trypsin,
demonstrating that it is at least in part polypeptide (Fig. 6).
Although activated ECI was not generally detectable in normal sera until it had
been fractionated (Fig. 4), the property ofactivatabilityand its apparent molecular
weight suggested a possible relationship ofECI to factors ofthe contact activation
pathway. Totestthis possibility, weobtained plasmasfrom patientsdeficient in factors
XI, XII, prekallikrein, and high molecular weight kininogen. HPLC size fraction-
ation ofeach sample generated normal titers ofECI. Thus ECI is neither identical
to the contact activation factors, nor dependent on these factors for activation.
Preliminary Studies ofthe Mechanism ofAction ofECI.
￿
In the presence ofantibody
andTNF, eosinophils form aggregates, particularly on thesurface ofthe target schis-
tosomula. ECI, but not control preparations, reduced the formation ofaggregates.
To determine whether ECI could suppress eosinophil function in the absence of a
living target organism, the effect ofECI on eosinophil adherence toplastic wastested.
In atypicalexperiment, TNFincreased eosinophil adherence by 367%, and an HPLC
fraction containing ECI reduced TNFenhanced adherence by 71%, with respect
to a control HPLC fraction.688
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FIGURE 6.
￿
Sensitivity ofECI
to heat or trypsin treatment.
The results in threeexperiments
with ECI (fractions 7-9 from
Fig. 3) from NR serumandfour
experiments with ECI from
different normal sera were es-
sentially similar; in order to
comparetheresults on thesame
scalethe level of killing in the
presence ofTNFwith no inhib-
itors present was set equal to
100%. Values represent the
mean percent maximumkilling
t SE (n = 7). Killing was as-
sayed under standard condi-
test sample
￿
tions when eosinophils were
stimulated with: (A) control
medium; (B) 100 U/ml of TNF; (C 100 U/ml of TNF plus (1% trypsin [two treatments with 0.5%
trypsin at 370C for 30 min]) plus soybean trypsin inhibitor (fourfold excess neutralizing units); (D)
TNFplus untreated ECI; (E) TNFplus treated ECI (treatment: 80°C for 1 h); (F)TNF plus treated
ECI; (1 htrypsin, then SBTI); (G) TNFplus ECI (1 h SBTI and trypsin together); (H) sample F with
fresh ECI added at end.
EC I did not have detectable toxic effects on eosinophils. The addition of ECI did
not affect the uptake of trypan blue by eosinophils incubated in assay medium for
periods up to 36 h or by nonadherent eosinophils removed from cytotoxicity cul-
tures. Furthermore, incubation of eosinophils in medium with ECI for 1 or 12 h
did not affect their ability to release H202, following stimulus with an optimal dose
of phorbol myristate acetate. In one experiment, for example, PMA increased the
rate of H202 production by a factor of 63.5 and 66 .3, respectively, for eosinophils
incubated 12 h with and without an optimal dose of ECI. By comparison, a 5-min
preincubation with 0.01% sodium azide (azide removedby washing) limited the in-
crease to a factor of 30.3 . Thus, the effect of ECI appeared to be a form of specific
regulation rather than a general toxicity.
The possibility was considered that ECI might have proteolytic activity, which
mightact by cleaving eosinophil surface moleculesinvolved in adhesion. To test ECI
for proteolytic activity, doses of ECI as high as 10 times the optimal concentration
(in the assay of eosinophil cytotoxic function) were mixed with 1251-labeled human
serum albumin or egg albumin PBS or in medium containing 10% FCS (as for the
eosinophil cytotoxicity assay). SDS gel electrophoresis detected significant degrada-
tion of the radiolabeled proteins by as little as 1 U/ml of trypsin in PBS, but no
degradation with any dose of ECI. Further, treatment of ECI with the irreversible
serine protease inhibitor diisopropyl fluorophosphate and dialysis in medium did
not affect its ability to suppress eosinophil cytotoxic function. These experiments
suggest that ifECI is aprotease, it is ofadifferent family and with ahighly restricted
specificity.
There are recent reports in the literature of factors from the urine of febrile pa-
tients that inhibit the toxic effects of TNF to tumor cell targets. Such substances
have been purified andappear to act by binding to the TNF molecule andpreventing
the interaction betweenTNF and itsreceptor on thetarget cell surface(22-24). The
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molecule known as uromodulin does not appear to inhibit the activity ofTNF in
standard tumor cell cytotoxicity assay, but its ability to bind to solid-phase TNF
suggests a role in the modulation of TNFmediated reactions (25). In view of this
evidence, we wanted to learn whether ECI acts by interfering with the interaction
of TNF and its receptor.
First, we considered whether the effects of ECI on eosinophils were specific for
TNF. When 20 pM GM-CSFwas used to stimulated eosinophil cytotoxic function,
selected control sera (Nos. 51, 52, 53, and 54 from the Red Cross collection, see
Fig. 2) (Table I) and various control HPLC sizing fractions (not shown) did not
affect cytotoxic function. However, NR serum, chromatographically purified ECI
from NR serum, and selected samples with detectable ECI (Nos. 25, 33, 41, and
67) all reduced the cytotoxic function ofGM-CSF-stimulated eosinophils (Table I).
Thus, the effect of ECI is not cytokine specific.
Next, ECI was tested for the ability to protect L929 cells from the toxic effects
ofTNF; it had no effect in the presence or absence of actinomycin D, when added
to the culture after various times ofincubation. In contrast, the TNFspecific mAb
245-10E11 protectedthe L929 cells whenadded during the first few hours ofculture.
Finally, we examined the time dependence of the effects of ECI on eosinophil-
mediated killing ofschistosomula targets. The inhibitory effect of NR serum (not
shown) or ECI (Fig. 7) could be observed when they were added to the eosinophils
aslate as 4 h afterthe TNF. mAb 245-10Ell also inhibited TNF-enhanced cytotoxic
function, but onlywhen it wasadded simultaneouslywiththe TNFto theeosinophils
(Fig. 7). In another set ofexperiments, ECI was added to the cultures at the begin-
ning, butwasremoved by washingat various times. The effect ofECI on eosinophil
cytotoxic function wasobservedwhen it waspresentforthefirst 2 h ofculture. When
TABLE I
Inhibition of Cytotoxic Function of GM-CSF-stimulated Eosinophils by ECI
" The percent maximum killing of schistosomula (maximum killing = GM-CSF
without inhibitor) assayed at 26-40 h, means of two experiments.
x Derived from NR serum, dilution factor relative to the serum = 50 .
S Samples 51-54 were selected for the absence of an inhibitory activity; samples
25, 33, 41, and 67 were selected for the presence of inhibitory activity (see
Fig. 2).
Inhibitor None
Cytokine stimulation
100 U/ml TNF
of eosinophils
20 pM GM-CSF
None 9' 48 100
1076 NR serum 23 24 33
20% ECII 13 27 46
Red Cross serum no.s
51 7 37 92
52 11 46 70
53 6 51 89
54 12 35 83
25 7 7 22
33 10 11 25
41 12 17 25
67 15 12 36690
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FIGURE 7.
￿
Time dependence
of the effects of ECI and mAb
245-IOEII on thecytotoxicfunc-
tion ofTNFstimulated eosino-
phils. 20% ECIor 1,000neutra-
lizing units of mAb 245-IOEII
was added to TNFstimulated
eosinophils at the indicated
timesofculture with schistoso-
mula-specific antibody andschis-
tosomula. Thecultures were in-
cubated furtherin orderto assay
of eosinophil cytotoxicfunction.
Thekillingofschistosomulawas
scored at 36-40 h.
it was removed after shorterdurations, the effects were diminished or undetectable
(Fig. 8). Preincubation ofeosinophils with ECI forup to 12 h at 37'C and removal
ofECI bywashingdid not reduce the subsequent cytotoxic functionofTNFstimulated
eosinophils. Thus, suppression ofcytotoxic function required the presence ofECI
for at least 2 h during the first 4-6 h of culture.
Taken together, the suppressive effect of ECI on GM-CSF-enhanced cytotoxic
function, the failure ofECI to protect L929 cells from the toxic effects ofTNF, and
the nature of time dependence show that ECI does not act by binding to TNF or
interfering with the initial interaction between TNF and the cell. ECI appears to
act directly on eosinophil expression of cytotoxic function.
Ultrastructural study of the eosinophil cytotoxic reaction against schistosomula
demonstrate that antibody-mediated dischargeofeosinophilgranule contents against
the target surface begins within 2 min ofcontact andcontinues for more than 12 h.
The target organisms begin to die after 8-12 h of culture, presumably as a result
ofcumulative damage to the tegument by toxic secretions (26). In this context, our
results suggest that ECI acts on an event early in the adherent and degranulation
functions of eosinophils against the targets.
In summary, we identified a human subject with a history ofsevere allergic der-
matitis, whose eosinophils and neutrophils frequently failed to respond to TNF in
FIGURE 8.
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￿
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￿
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in vitroassays. Serafrom this subject, from twopatientswith severe hypereosinophilia,
and from 4 of 100 anonymous donors contained a substance (ECI) that suppressed
the cytotoxic function ofcytokine stimulated eosinophils. ECI is a polypeptide of
80-100 kDa. ECI or an inactive precursor ofECI was present in all sera that were
tested. Fractionation ofsera increased irreversibly the activity of ECI. Collectively,
the association ofserum ECI with inflammation and the in vitro activities of ECI
suggest thatthis substanceis part ofanatural feedback mechanism tosuppress func-
tions of cytokine-stimulated eosinophils in inflammation.
Summary
A human subject (NR) was identified whose eosinophils and neutrophils failed
to respond to TNF in vitro in 29 of33 experiments, using several biological assays.
There was a response rate to TNF of100% among37 control subjects whose leuko-
cytes were tested in parallel. NR serum contained an activity thatinhibited thecyto-
toxicfunction ofTNF-andGM-CSF-stimulated normal humaneosinophils. Asimilar
activity was detected in 4 of122 control sera and in seraoftwo subjects with hyper-
eosinophilia. This activity (ECI)hadan apparent molecularweight of80,000-100,000
and was sensitive to heating at 80°C or to trypsin treatment. HPLC sizing chroma-
tography increased the titer ofECI by a factor of50 to 2,000 in experiments using
NR serum or other sera with detectable inhibitory activity. In seven experiments
usingsera with no inhibitory activity, HPLC generated ECI ofthe same apparent
molecular weight. The effect ofHPLC on ECI activity required the separation of
serum components and did not result from exposure to HPLC system components
or othersample processing methods. This suggests that ECI in serum can be stabi-
lized in an inactive or partially active form and that HPLC removes the stabilizing
component. ECIsuppressed TNFstimulated eosinophil cytotoxicfunctionwhenadded
to cultures up to 4 h after exposure of eosinophils to cytokine. However, ECI did
not protect L929 cells from the toxic effects of THE Thus, ECI did not act by
preventing the initial interaction ofTNF witheosinophils or by interfering with the
bindingofTNF to its receptor on L929 cells. The results suggest that ECI is a com-
ponent ofa feedbackmechanism that suppresses functions ofcytokine-activated eo-
sinophils in inflammation.
We thankDr.JocelynSpraggforhelpfuldiscussionsand forcriticalreview ofthemanuscript.
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